

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/32, 7/48	A1	(11) International Publication Number: WO 99/26597 (43) International Publication Date: 3 June 1999 (03.06.99)
(21) International Application Number: PCT/EP98/07535 (22) International Filing Date: 18 November 1998 (18.11.98) (30) Priority Data: 9724802.5 24 November 1997 (24.11.97) GB (71) Applicant (for AU BB CA CY GB GD GH GM IE IL KE LC LK LS MN MW NZ SD SG SL SZ TT UG ZW only): UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB). (71) Applicant (for all designated States except AU BB CA CY GB GD GH GM IE IL KE LC LK LS MN MW NZ SD SG SL SZ TT UG ZW): UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL). (72) Inventor: PARROTT, David, Terence; Unilever Research Port Sunlight, Quarry Road East, Bebington, Wirral, Merseyside L63 3JW (GB). (74) Agent: PEARCE, Tim; Unilever PLC, Patent Dept., Colworth House, Sharnbrook, Bedford MK44 1LQ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTIPERSPIRANT OR DEODORANT COMPOSITIONS (57) Abstract Deodorant and antiperspirant compositions can suffer from perceived irritancy when applied topically, which can be ameliorated or overcome by incorporating within the composition borage seed oil, and especially an amount selected in the range of from 0.5 to 10 wt.%. The compositions advantageously comprise an aluminium or aluminium-zirconium active.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

The invention relates to antiperspirant or deodorant compositions. In particular it relates to antiperspirant or
5 deodorant compositions comprising borage seed oil.

The antiperspirant market is dominated with products based on aluminium or zirconium salts which are intended to prevent, or at least control, perspiration at the skin
10 surface, particularly on the underarm, whilst often simultaneously providing a perceived degree of deodorancy.

In contrast, deodorants are formulations which are designed to either mask malodour or prevent its formation by reducing
15 the local micro-organism population.

Antiperspirant and deodorant compositions are utilised in many product forms e.g. roll-ons, creams, sticks, aerosols and pump sprays. However all forms suffer from a number of
20 common disadvantages.

A principal disadvantage of many deodorants and antiperspirants is their perceived skin unfriendliness. More particularly, the presence of volatile carriers such as
25 volatile silicones and ethanol, and indeed deodorant and antiperspirant actives as well as a host of other ingredients commonly employed in deodorant and antiperspirant formulations is perceived to have an adverse effect, in particular on irritant effect, on a user's skin
30 following application. Irritation can be ameliorated by lowering the amount of an active ingredient in the composition or by reducing the active's penetration through the skin. A serious drawback of both approaches is that the efficacy is impaired.

Adverse effects deter many consumers from utilising deodorants and antiperspirants thereby depriving the consumer of the benefits to be derived from such cosmetics.

5 An object of the invention is to provide such a composition which has excellent antiperspirant or deodorant efficacy, excellent cosmetic properties and aesthetics with reduced or no irritation.

10 European Patent Application 0416855 (Efamol) discloses treatment of skin damage due to radiotherapy with gamma linolenic acid (GLA) and also teaches a variety of suitable plant sources of GLA, including Borage species. PCT application WO 90/07331 (Went) teaches treatment of
15 inflammation arising from arthritis or headache by topical application of GLA; borage seed is taught as a suitable source. European Patent Application 0173478 (Efamol) discloses treatment of inflammatory skin disorders with compositions containing GLA and glucocorticoids; borage
20 species such as *Borago officinalis* is mentioned as a rich source of GLA. French patent 2,704,390 (Boiron) discloses an oral supplement containing borage seed oil to provide anti-aging benefits to skin. French patent 2,604,624 (Parfums Rochas) discloses skin care compositions containing
25 polyunsaturated carboxylic acids, such as GLA; borage is said to be rich in GLA. U.S. Patent 5,445,822 (Bracco) discloses cosmetic compositions containing polyunsaturated acids such as GLA.

30 Great Britain Patent 2,271,928 (Laing) discloses the use of borage family plant extracts for alleviation of skin disorders and irritations.

35 Tolleson et al., "Transepidermal Water Loss and Water Content in the Stratum Corneum in Infantile Seborrheic

Dermatitis", Acta Derm Venereol (Sweden), Feb. 1993, 73 (1), p. 18-20, disclose the use of topically applied borage oil for treatment of seborrheic dermatitis. Bahmer et al., "Treatment of Atopic Dermatitis with Borage Seed Oil (Glandol) - A Time Series Analytic Study", Kinderarztl Prax (Germany), Oct. 1992, 60 (7), p. 199-202, disclose the use of borage oil for the treatment of atopic dermatitis.

The art does not teach the use of GLA or borage seed oil to reduce irritation or sting associated with the use of deodorants or antiperspirants. We found that among GLA containing plant sources borage seed oil was particularly effective at ameliorating irritation and that this effect could not be attributed merely to the presence of GLA in the borage seed oil. We also found that borage seed oil was more effective than other, non-GLA-containing anti irritants.

Surprisingly, we have found that borage seed oil can be incorporated into an antiperspirant or deodorant cosmetic composition to produce a composition which has improved and attractive cosmetic characteristics expected of such compositions as well as excellent efficacy, low irritation potential and non-stinging upon application.

According to the invention there is provided an antiperspirant or deodorant cosmetic composition suitable for topical application to the human skin, comprising:

- i. an antiperspirant or deodorant active;
- ii. a carrier for the antiperspirant or deodorant active; and
- iii. borage seed oil.

Where the formulation is an antiperspirant it commonly comprises 1-35% by weight of the composition of an antiperspirant active.

5 Borage seed oil is obtained from the seeds of borage plant,
also known as *Borago officinalis* L. (Boraginaceae), which is
an herbaceous annual plant, native to Europe, Asia Minor and
North Africa, naturalized in the United States. The seed oil
contains: gamma-linolenic acid (GLA), ~24%, sterols (e.g.,
campesterol and sitosterol), tocopherols, linoleic acid
(~38%), oleic acid (~14.5 - 23%), palmitic (~4.7%),
amabiline, etc. See Whipkey et al., "In Vivo and In Vitro
10 Lipid Accumulation in *Borago officinalis* L.", JAOCS, 65 (6),
979-984 (1988); and Leung et al., "Encyclopedia of Common
Natural Ingredients Used in Food, Drugs and Cosmetics", 2nd
ed., John Wiley & Sons, Inc., New York (1996).

15 Borage seed oil is employed according to the present
invention to reduce or eliminate the skin irritation and/or
sting caused by co-components of the antiperspirant or
deodorant composition according to the invention.

20 The amount of borage seed oil in the inventive compositions
ranges generally from at least 0.05%, preferably from 0.1% to
20%, most preferably from 0.5% to 10%. In some compositions
it is convenient to employ a concentration of up to 5 wt%
such as 0.5 to 1 wt%.

25 An antiperspirant composition according to the invention
comprises an antiperspirant active. Examples of suitable
actives include aluminium salts, zirconium salts, aluminium
and/or zirconium complexes, for example aluminium halides,
30 aluminium hydroxy halides, zirconyl oxyhalides, zirconyl
hydroxyhalides, and mixtures thereof. Specific examples
include activated aluminium chlorohydrate, aluminium
chlorohydrate, aluminium pentachlorohydrate and aluminium
zirconiumchlorohydrate. Useful zirconium salts include
35 zirconium hydroxy-chloride and zirconium oxychloride. Other

generally used actives will be known to those skilled in the art. Preferred actives include AAZG (Activated Aluminium Zirconium Glycine), ZAG (Zirconium Aluminium Glycine), and AACH (Activated Aluminium Chlorohydrate). The antiperspirant active can be present in particulate form or in solution, such as for example in aqueous solution, advantageously 30 to 60% by weight solution.

The amount of antiperspirant active present in the composition according to the invention may be from 1-35% by weight of the composition, preferably from 10-30% by weight and more preferably 20-30% by weight of the composition.

The deodorant compositions according to the invention normally comprise 0.01 to 90% of a deodorant active. The deodorant active used in the cosmetics of the invention can be any deodorant active known in the art such as alcohols, in particular aliphatic monohydric alcohols such as ethanol or propanol, antimicrobial actives such as polyhexamethylene biguanides eg Cosmocil™ or chlorinated aromatics, eg Triclosan™, non-microbiocidal deodorant actives such as triethylcitrate, bactericides and bacteriostatis.

The carrier material for the antiperspirant composition according to the invention can also comprise one or more of volatile carrier fluids, one or more of non-volatile emollients, and one or a combination of thickener and/or structurant materials if required. The carrier material, including, where relevant, carrier materials providing additional properties such as emolliency, can often comprise up to about 90 wt% of the composition, in many instances from 5 to 80 wt% and particularly from 10 to 70 wt%. Where the composition comprises both hydrophylic and hydrophobic phases, the weight ratio of the two phases is often in the range of 10:1 to 1:10. Aerosol compositions according to

the present invention can conveniently be obtained by introducing a base formulation as described herein that is free from propellant and at least 0.7 times and often 1.5 to 20 times its weight of propellant into a suitable aerosol dispenser.

The antiperspirant or deodorant composition can comprise a mixture of particulate solids or a suspension of solids in a liquid medium, which can be thickened to reduce the rate of segregation or structured to produce a cream (soft solid) or solid. Alternatively the composition can comprise a mixture of liquid constituents, including a solution of an active in a carrier, such a composition often adopting the form of an oil in water or water in oil emulsion, which may be thickened or gelled.

The carrier material, which may be a fluid or a mixture of fluids, is often selected according to the physical form of the cosmetic composition, e.g. volatile low viscosity silicones, low molecular weight hydrocarbons, alcohols with the exception of ethanol, and water, and can be selected by those skilled in the art to provide appropriate physical and sensory properties for the product.

Volatile silicones are usually selected from cyclic polysiloxanes containing from 3 to 8 dialkylsilicone groups, especially dimethylsilicone groups and particularly 4 or 5 dimethylsilicone groups. Other useful volatile silicones can comprise linear polysiloxanes, preferably containing 4 or 5 alkylsiloxane groups, including terminal groups. Low molecular weight liquid hydrocarbons can comprise paraffin oils. Suitable alcohols can comprise monohydric alcohols, such as C3 to C10 aliphatic alcohols, dihydric alcohols such as glycol or propylene glycol or polyhydric alcohols such as glycerol or sorbitol. Carrier materials can provide

additional desirable properties, such as polyhydric alcohols for example glycerol can act as a moisturising agent and volatile cyclomethicones can act as emollients..

5 The non-volatile emollient, if used in the composition, may consist of a single emollient compound or a mixture of emollients, and can typically include fatty acids and fatty alcohol esters, slightly water soluble ethers and alcohols, hydrocarbons, water insoluble ethers, mineral oils and
10 polyorganosiloxanes, and mixtures thereof.

Non-volatile silicones are often polyalkylsiloxanes, polalkylarylsiloxanes or polyethersiloxanes having a viscosity of above 10 mPa.s, such as up to about 5×10^6 mPa.s
15 at 25°C, including polymethylphenylsiloxanes or dimethylpolyoxyalkylene ether copolymers.

Emollient aliphatic esters, often containing from about 12 to 25 carbons, and preferably one substituent containing a
20 chain of at least 12 carbons. examples include cetyl palmitate, butyl myristate, glyceryl stearate and propylene glycol monolaurate. The composition can comprise a liquid aliphatic ether which can provide emolliency, such as ethers derived from polyalkylene glycols and a low weight (eg up to
25 C6) alcohol, such as polypropylene glycol (10-15) butyl ether.

The total amount of emollient materials within the composition, excluding borage oil, is often within the range
30 of from 1 to 70 wt%.

The thickening or structurant agent, when required, is selected according to the product form of the cosmetic composition. The thickening or structuring agent can be
35 organic (monomeric or polymeric) or inorganic and is usually

chosen depending on the physical nature of the liquid phase to be thickened or structured, such as whether it is hydrophobic or hydrophylic. The amount is normally selected in order to attain the desired viscosity or the liquid or cream or desired resistance to penetration of a solid in accordance with the present invention. It can be any of a number of materials, including, for example, waxy structurants for a hydrophobic composition or phase including hydrogenated vegetable oil, hydrogenated castor oil, fatty acids, such as hydroxystearic acid, beeswax, paraffin wax, microcrystalline waxes, silicone wax, and fatty alcohols, such as stearyl alcohol. Polymeric materials for thickening include polymers such as polyamides, hydroxypropylcellulose, and natural or synthetic gums, such as polyglycerides including agar, agarose, pectin, or guar or mixtures or combinations thereof. A further class of polymers that is particularly directed to structuring an oil phase containing a silicone oil comprises polysiloxane elastomers. Suspending agents such as silicas or clays such as bentonite, montmorillonite or hectorite, including those available under the trademark Bentone can also be employed to thicken liquid compositions according to the invention. The composition can be thickened with non-polymeric organic gellants, including selected dibenzoyl alditols (eg dibenzoyl sorbitol) or selected n-acyl amino derivatives (eg N-acyl glutamide derivatives) or selected hydroxyfatty acids (eg 12-hydroxystearic acid) or selected sterols (eg cholesterol) or selected secondary amides of di or tri basic carboxylic acids, (eg 2-dodecyl-N,N'-dibutylsuccinimide) by themselves or in combination.

The amount of structurant or thickening agent that should be employed in the invention compositions will depend upon the viscosity of a fluid formulation or extend of hardness of a

solid formulation that the producer wishes to attain. The amount to be employed will in practice also vary depending on the chemical nature of the structurant or thickening agent. In many instances, the amount of structurant or thickening agent will be selected in the range of from 0.1 to 20 wt%, and particularly from 1 to 15 wt%.

The composition according to the invention can optionally comprise other ingredients, in addition to those already identified, depending on the nature and form of the finished product.

Other ingredients common to the art can also be included in the compositions according to the invention. These include surfactants, fillers, fragrances, preservatives and colouring agents for example. These ingredients are selected according to the physical and chemical form of the cosmetic composition.

Surfactants can comprise optionally up to 25%, more commonly up to 5% by weight of the total product, and are particularly useful in formulating emulsion antiperspirant or deodorant compositions, for example for use as pump spray or roll-on formulations. However for other product types, it is preferred that the composition contains less than about 8% by weight of surfactants. Non-ionic surfactants are particularly preferred. It is often convenient to select a mixture of surfactants, such as one having a comparatively high HLB value, eg 8 to 18, and one having a comparatively low HLB value, eg 2 to 8, which can be introduced in suitable relative proportions to to attain an average HLB value of about 6 to 12.

Many suitable nonionic surfactants are selected from nonionic esters, ethers or amine oxides having an

appropriate HLB value. Many preferred ionic surfactants comprise a polyoxyalkylene moiety, especially a polyoxyethylene moiety eg 2 to 80, especially 5 to 60 oxyethylene units, or possibly with a polyoxypropylene content, to provide hydrophilicity. Other moieties providing hydrophilicity include polyhydric alcohols such as sorbitol or glycerol. The hydrophobic moiety is commonly derived from aliphatic alcohols or acids or amines containing about 8 to 50 carbons and particularly 10 to 30 carbons. Examples of suitable nonionic surfactants include cetareth-10 to -25, ceteth-10-25, steareth-10-25, and PEG-15-25 stearate or distearate. Other suitable examples include C10-C20 fatty acid mono, di or tri-glycerides. Further examples include C18-C22 fatty alcohol ethers of polyethylene oxides (8 to 12 EO). Examples of surfactants which typically have a low HLB value, and often of from 2 to often comprise mono or possibly di fatty acid esters of polyhydric alcohols such as glycerol, sorbitol, erythritol or trimethylolpropane, including cetyl, stearyl arachidyl and behenyl. Other examples include monoglycerides of palmitic or stearic acid, sorbitol mono or diesters of myristic palmitic or stearic acid, and trimethylolpropane monoesters of stearic acid.

Fillers can comprise up to about 20%, more commonly up to 10% of the total product and are normally less costly than the essential components of the invention, thereby reducing overall cost. Suitable fillers include aluminium stearate, aluminium tri-stearate, calcium stearate, talc or finely divided polyethylene, an example of which is ACUMIST B18.

Fragrances, when present, typically comprise up to about 1% of the total product.

Colouring agents and preservatives can be added as desired.

Other optional ingredients are other cosmetic adjuncts conventionally employed in antiperspirant or deodorant products.

5

The ingredients which can optionally be present in the composition carrier can conveniently form the balance of the composition.

10

Propellants commonly employable in aerosol compositions herein comprise hydrocarbons (or much less desirably halohydrocarbons) having a boiling point of below 10°C and especially those with a boiling point below 0°C. It is especially preferred to employ liquified hydrocarbon gasses, and especially C₃ to C₆ hydrocarbons, including propane, isopropane, butane, isobutane, pentane and isopentane and mixtures of two or more thereof. Preferred propellants are isobutane, isobutane/isopropane, isobutane/propane and mixtures of isopropane, isobutane and butane.

15

20

The composition according to the invention can take any form of a product suited to or adapted for topical application to human skin, and is usually contained in a suitable holder or dispenser to enable it to be applied to the area of the skin, particularly the underarm, where control of perspiration and deodorancy is required.

25

Example 1

30

Twenty healthy male/female volunteers, who were between the ages of 18 and 55, were recruited for each test.

Test Patches

Patches consisted of a compartmented strip of Al-test units (Finn chambers of 0.8cm internal diameter) fixed onto 5cm wide occlusive Scanpor tape manufactured by Norgesplaster, Norway. Ten compartments were used in these studies to contain the ten test samples.

Test Procedure

The protocol adopted for these studies were of the double-blind, within subject comparison type. They were conducted on twenty healthy volunteers per test.

It is a safety clearance condition of forearm patch testing that panellists have a "rest period" of 3 weeks before a forearm site can be repatched.

Protocol

Patches were prepared by placing a small amount of petroleum jelly (White Petroleum Jelly ex. Boots) in the bottom of each test chamber, followed by a filter paper onto which the test material was dosed. One drop of each test product was dosed in turn onto a filter paper using a Pastette alpha 1.0ml plastic pipette supplied by Orme scientific. This constituted on average a dose of approximately 0.02g. In the case of the aerosol product it was sprayed directly on to the filter paper (in a ventilated spray booth) and the filter paper was then inserted into the appropriate Finn chamber immediately before patching (the average dosage of the aerosol was estimated from the results from 20 such saturated filter papers. Products were randomised across patch sites. Panellists were instructed to keep patches clean and dry when in place.

5 Panellists reported on the Monday morning of the test week when they had a patch applied to clear skin of one inner forearm. These patches remained in place for 24 hours when panellists again reported and the patch was removed. They returned six hours later for assessment of each of the patch sites. Fresh patches, using the same product randomisation, were applied. These patches remained in place for 18 hours, panellists again reported and the patch was removed; again 10 the patches were graded six hours later. This repatching/grading was repeated on Thursday and Friday. A final recovery reading was performed on the following Tuesday morning - i.e. 5 gradings were performed in total. The readings six hours after the final patch removal were of most 15 interest. One potential issue with this protocol (highlighted during the safety clearance process) was 'tape reaction' due the multiple application and removal of tape from the same forearm site. Therefore the degree of tape reaction was also recorded using the same grading scale as 20 used for the patch sites.

The score for each test was graded according to the Patch Grading Scale. The score for each sample was averaged to produce a final score.

Patch Grading Scale

Grade	Description
0.0	No apparent cutaneous involvement.
0.5	Faint, barely perceptible erythema or slight dryness
1.0	Faint but definite erythema, no eruptions or broken skin or no erythema but definite dryness; may have epidermal fissuring.
1.5	Well defined erythema or faint papules with definite dryness, may have epidermal fissuring.
2.0	Moderate erythema, may have very few papules or deep fissures, moderate to severe erythema in the cracks.
2.5	Moderate erythema with barely perceptible oedema or severe erythema not involving a significant portion of the patch (halo effect around the edges), may have a few papules or moderate to severe erythema.
3.0	Severe erythema (beet redness), may have generalized papules or moderate to severe erythema with slight oedema (edges well defined by raising).
3.5	Moderate to severe erythema with moderate oedema (confined to patch area) or moderate to severe erythema with isolated eschar formations or vesicles.
4.0	Generalized vesicles or eschar formations or moderate to severe erythema and/or oedema extending beyond the area of the patch.

Results

Sample	Description	Score
1	Standard AP Stick ⁽¹⁾	0.79
2	Standard AP Stick + 17.5% Borage Seed Oil	0.35
3	Standard AP Aerosol ⁽²⁾	0.79
4	Standard AP Aerosol + 6.4% Borage Seed Oil	0.26

Standard statistical analyses showed that sample 2 was significantly milder than sample 1 and that sample 4 was significantly milder than sample 3.

Example 2

The following is an antiperspirant stick formulation according to the invention. It can be made by standard methods known in the art.

Stick Example:	
AZAG	24%
Estol EO4DS	1%
Casterwax	4%
Lorol C18 deo	14%
Talc	3.2%
Perfume	1%
Volatile Silicone DC345	35.3%
Borage Seed Oil	17.5%

- (1) Comprising 24% AZAG; 1% ESTOL EO4DS; 4% Casterwax; 14% Lorol C₁₈ deo; 3.2% Talc; 1% perfume; and 52.8% volatile silicone DC345.
- (2) Comprising 10% AACH; 1% Bentone 38; 1.0% perfume; 13% volatile silicone Q2 1465 and 75% propellant.

Example 3

5 The following is an antiperspirant aerosol formulation according to the invention. It can be made by standard methods known in the art.

Aerosol Example:	
AACH	10.0%
Bentone 38	1.0%
Perfume	1.0%
Volatile Silicone Q2 1465	6.6%
Borage Seed Oil	6.4%
Propellant CAP 40	75%

Claims:

1. An antiperspirant or deodorant cosmetic composition suitable for topical application to the human skin, comprising:
 - i. an antiperspirant or deodorant active;
 - ii. a carrier for the antiperspirant or deodorant active; and
 - iii. borage seed oil.
2. A composition according to claim 1 characterised in that it comprises from 0.1 to 20% by weight and preferably 0.5 to 10% by weight of the borage seed oil.
3. A composition according to either claim 1 or 2 characterised in that it comprises from 10 to 30% by weight antiperspirant active.
4. A composition according to any preceding claim characterised in that the antiperspirant active contains zirconium.
5. A composition according to any preceding claim characterised in that it comprises a volatile silicone carrier, preferably in an amount of from 10 to 70 wt%.
6. A composition according to any preceding claim characterised in that it comprises a structurant or thickening agent in a concentration sufficient to produce a stick or cream.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/07535

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K7/32 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 330 140 A (BRISTOL MYERS CO) 30 August 1989 see the whole document ---	1-6
Y	GB 2 271 928 A (LAING ROSE MARY ELIZABETH) 4 May 1994 cited in the application see abstract see claims ---	1-6
A	RALF DIETER MERKLE: "öle in der Kosmetik" SOFW:SEIFEN, ÖLE,FETTE, WACHSE JOURNAL , vol. 118, no. 16, 11 October 1992, pages 991-999, XP000307087 Augsburg see page 991, left-hand column see the whole document --- -/--	1,2

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

13 April 1999

Date of mailing of the international search report

21/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pelli Wablat, B

INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/EP 98/07535

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 90 07331 A (WENT NOEL JAMES) 12 July 1990 cited in the application see claims 1,3 ---	1,2
A	EP 0 310 252 A (PROCTER & GAMBLE) 5 April 1989 see page 3, line 36 - line 48 see page 4, line 13 - line 57 -----	1,3-6

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 98/07535

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0330140	A	30-08-1989	AU 3022289 A JP 1301615 A	24-08-1989 05-12-1989
GB 2271928	A	04-05-1994	NONE	
WO 9007331	A	12-07-1990	AU 629286 B	01-10-1992
EP 0310252	A	05-04-1989	US 4853214 A AT 119026 T CA 1328222 A DE 3853186 D DE 3853186 T GR 3015247 T	01-08-1989 15-03-1995 05-04-1994 06-04-1995 07-09-1995 30-06-1995